Abstract
Omalizumab is a humanized monoclonal antibody which selectively binds to IgE and is employed to manage moderates to severe allergic asthma. It decreases severity of asthma episodes and enhances global asthma management particularly in patients who are non compliant with other treatments. Objectives: In this study, the effectiveness of safety as well as the clinical result of the Omalizumab in patient diagnosed with moderate to severe allergic asthma will be assessed. Study design : A Systematic Review Methods : An extensive search was performed with databases such as PubMed and Cochrane to identify the systematic review of randomized controlled trials and observational studies. Trials comparing the effect of Omalizumab for exacerbation frequency, lung capacity, and endpoints of safety for patients with asthma were included. Results : mean age in the reviewed studies was 39. 5 years with a standard deviation of 10. 2. The rate of asthma exacerbation was significantly lower in the omalizumab group compared to placebo group (p < 0. 01); mean improvement of FEV1 was 12% compared with placebo (p < 0. 05). They also managed to cut down on the use of corticosteroids for their patients, thus improving overall long-term effects. The safety profiles were acceptable with mild to moderate AE being more often reported (p < 0. 05). Conclusion : Omalizumab is identified as beneficial in managing moderate to severe allergic asthma with the ability to decrease the frequency of exacerbation and corticosteroids usage while improving lung function and quality of life.
Keywords: Omalizumab, allergic asthma, exacerbation, IgE
African Journal for Biological Sciences